Transplantation and cellular therapy
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Early T-cell Large Granular Lymphocyte Expansions in Patients with Cytopenias after CD19 CAR T-cell Therapy.
2026
-
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
2026
-
CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL.
2026
-
Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges..
32:1313.e1-1313.e12.
2026
-
The Influence of Race/Ethnicity and Social Vulnerability on Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant in Older (≥60 Years) Adults..
32:1243.e1-1243.e3.
2026
-
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations..
32:881.e1-881.e12.
2026
-
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation..
32:877.e1-877.e11.
2026
-
Comment on "Can Cord Blood Unit Selection Improve Outcomes After Single-Unit Unrelated Cord Blood Transplantation for Non-Remission Acute Myeloid Leukemia?"..
32:1030.e1-1030.e2.
2026
-
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma..
32:676.e1-676.e14.
2026
-
Vitamin D Deficiency and Efficacy of Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation..
32:552.e1-552.e4.
2026
-
Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis..
32:503.e1-503.e9.
2025
-
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation..
32:74.e1-74.e14.
2025
-
Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study..
32:94.e1-94.e10.
2025
-
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML..
32:76.e1-76.e12.
2025
-
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT..
31:959-972.
2025
-
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR..
31:973-988.
2025
-
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment..
31:824.e1-824.e13.
2025
-
Assessing cognitive function in transplantation and chimeric antigen receptor t cell therapy recipients: Expert recommendations from the survivorship, aging and biobehavioral special interest groups of the American Society for Transplantation and Cellular Therapy..
31:756-773.
2025
-
Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT..
31:774-788.
2025
-
Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT..
31:742-755.
2025
-
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines..
31:285-296.
2025
-
Courage To Try Something New..
30:1115-1117.
2024
-
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort..
31:36-44.
2024
-
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies..
30:1139-1154.
2024
-
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation..
30:1013.e1-1013.e12.
2024
-
In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy..
30:942-954.
2024
-
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma..
30:990-1000.
2024
-
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy..
30:788.e1-788.e9.
2024
-
Transplantation-Associated Altered Mentation and Encephalopathy: A New Classification for Acute Neurocognitive Changes Associated with Hematopoietic Cell Transplantation from the ASTCT Committee on Practice Guidelines..
30:646-662.
2024
-
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients..
30:415.e1-415.e16.
2024
-
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis..
29:515.e1-515.e7.
2023
-
The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients..
29:632.e1-632.e10.
2023
-
TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia..
29:390.e1-390.e10.
2023
-
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab..
29:314-320.
2023
-
Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy..
29:259.e1-259.e10.
2022
-
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease..
29:179.e1-179.e10.
2022
-
Allogeneic Transplantation for Older Patients with Acute Myeloid Leukemia: The Dawn of a New Era..
28:793-794.
2022
-
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies..
29:113-118.
2022
-
Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion..
29:36.e1-36.e5.
2022
-
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology..
29:10-18.
2022
-
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood..
29:52.e1-52.e9.
2022
-
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)..
28:810-821.
2022
-
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma..
28:751.e1-751.e7.
2022
-
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years..
28:498.e1-498.e9.
2022
-
eHealth-Generated Patient Data in an Outpatient Setting after Hematopoietic Stem Cell Transplantation: A Scoping Review..
28:463-471.
2022
-
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma..
28:401.e1-401.e7.
2022
-
Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission..
28:368.e1-368.e7.
2022
-
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy..
28:305.e1-305.e9.
2022
-
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review..
28:294-302.
2022
-
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults..
28:309.e1-309.e9.
2022
-
Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation..
28:277.e1-277.e6.
2022
-
Home-Based Hematopoietic Cell Transplantation in the United States..
28:207.e1-207.e8.
2022
-
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant..
28:473-482.
2022
-
Transplantation for Older Adults-More Questions than Answers..
27:955-956.
2021
-
Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection..
28:55.e1-55.e5.
2021
-
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy..
27:993.e1-993.e8.
2021
-
Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation..
27:934.e1-934.e6.
2021
-
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation..
27:784.e1-784.e7.
2021
-
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report..
27:817-835.
2021
-
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy..
27:771.e1-771.e10.
2021
-
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies..
27:669.e1-669.e8.
2021
-
Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults..
27:617.e1-617.e7.
2021
-
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves..
27:438.e1-438.e6.
2021
-
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay..
27:431.e1-431.e8.
2021
-
Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation..
27:262.e1-262.e11.
2021
-
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies..
27:255.e1-255.e9.
2020
-
Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival..
27:337.e1-337.e7.
2020
-
Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients..
27:181.e1-181.e9.
2020
-
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
2024
-
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years
2022
Identity
International Standard Serial Number (ISSN)